JUSTIN HASLAM: Open Payments
NPI 1033729512 · OGDEN, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$773 in 45 payments from 19 companies in 2025. Trend: 2023 $885 · 2024 $931 · 2025 $773
Food & beverage: $773
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $148 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $135 |
| Lilly USA, LLC | 5 | $78 |
| AstraZeneca Pharmaceuticals LP | 4 | $65 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $39 |
| GlaxoSmithKline, LLC. | 2 | $35 |
| SI-BONE, INC. | 1 | $27 |
| Amgen Inc. | 1 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $25 |
| Lundbeck LLC | 1 | $24 |
Products named: CAPLYTA, MOUNJARO, VRAYLAR, UBRELVY, QULIPTA, XIFAXAN, FARXIGA, TRELEGY ELLIPTA.
Industry payments across UT — which companies pay providers there.
